Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATHENAHEALTH INCATHN · Entity 160326 | Director | June 06, 2018 | June 08, 2018 |
| CareDx, Inc.CDNA · Entity 4344 | Director | January 22, 2019 | January 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATHENAHEALTH INC
Report date June 06, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,976 |
Reported balance
After 2018-06-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-06 · Grant · Acquired 1,931 · Balance 5,976 F1: Represents an award of restricted stock units ("RSUs") under the Issuer's 2007 Stock Option and Incentive Plan, as amended and restated (the "2007 Plan"), granted pursuant to the Issuer's 2018 Director Compensation Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs fully vest on June 6, 2019. F2: Includes 1,931 units of common stock that were granted pursuant to RSU awards under the 2007 Plan. The RSUs are subject to time-based vesting and will be settled only in stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") under the Issuer's 2007 Stock Option and Incentive Plan, as amended and restated (the "2007 Plan"), granted pursuant to the Issuer's 2018 Director Compensation Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs fully vest on June 6, 2019.
F2: Includes 1,931 units of common stock that were granted pursuant to RSU awards under the 2007 Plan. The RSUs are subject to time-based vesting and will be settled only in stock.
CareDx, Inc.
Report date January 22, 2019 · Filed January 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,837 |
Reported balance
After 2019-01-22 transaction · row 1
1 source rowRow 1 · 2019-01-22 · Exercise / conversion · Acquired 5,000 · Balance 15,837 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.88 · Expires 2028-07-01 | Direct | 25,000 |
Reported balance
After 2019-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-22 · Exercise / conversion · Disposed 5,000 · Balance 25,000 F1: 1/36th of the shares subject to the option vested on August 2, 2018 and 1/36th of the shares subject to the option vested or vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/36th of the shares subject to the option vested on August 2, 2018 and 1/36th of the shares subject to the option vested or vest monthly thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EQRx, Inc.
Report date November 09, 2023 · Filed November 09, 2023
Section 16 reporting ended · disclosed 2023-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-09 transaction · row 1
1 source rowRow 1 · 2023-11-09 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 · Expires 2032-02-25 | Direct | 0 |
Reported balance
After 2023-11-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-09 · Disposition to issuer · Disposed 389,223 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time. F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.
F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time.
F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2023 Filed Nov 9, 2023 16:06 UTC | EQRx, Inc. EQRX · Entity 108311 | Disposition to issuerStock Option (Right to Buy) · Derivative | 389,223 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0000899243-23-020292 · doc4.xml · derivative · entry 2 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 389,223 shares Expires 2032-02-25 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time. F4 · derivative.exercise_date: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration). Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 16:06 UTC | EQRx, Inc. EQRX · Entity 108311 | Disposition to issuerCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-020292 · doc4.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2 · price: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:07 UTC | EQRx, Inc. EQRX · Entity 108311 | GrantStock Option (Right to Buy) · Derivative | 101,010 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001104659-22-106025 · tm2227449-8_4seq1.xml · derivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,010 Underlying: Common Stock · 101,010 shares Expires 2032-09-30 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan). Read SEC document |
| September 30, 2022 Filed Feb 22, 2023 16:07 UTC Amendment | EQRx, Inc. EQRX · Entity 108311 | GrantStock Option (Right to Buy) · Derivative | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-024299 · tm237528-2_4aseq1.xml · derivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires not disclosed F1 · derivative.exercise_price: This Form 4/A amends and restates the original Form 4 filed on October 4, 2022 (the "Original Form 4"). The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person. F1 · shares: This Form 4/A amends and restates the original Form 4 filed on October 4, 2022 (the "Original Form 4"). The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person. F1 · derivative.exercise_date: This Form 4/A amends and restates the original Form 4 filed on October 4, 2022 (the "Original Form 4"). The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person. F1 · derivative.expiration_date: This Form 4/A amends and restates the original Form 4 filed on October 4, 2022 (the "Original Form 4"). The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 17:27 UTC | EQRx, Inc. EQRX · Entity 108311 | GrantStock Option (Right to Buy) · Derivative | 449,644 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001213900-22-010122 · ownership.xml · derivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,644 Underlying: Common Stock · 449,644 shares Expires 2032-02-25 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on December 17, 2022, with the remainder vesting in eight substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 25, 2022 Filed Feb 22, 2023 16:05 UTC Amendment | EQRx, Inc. EQRX · Entity 108311 | GrantStock Option (Right to Buy) · Derivative | 389,223 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001104659-23-024293 · tm237528-1_4aseq1.xml · derivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,223 Underlying: Common Stock · 389,223 shares Expires 2032-02-25 F1 · shares: This Form 4/A amends and restates the original Form 4 filed on March 1, 2022 (the "Original Form 4"). The number of shares of Common Stock subject to the stock option granted to the Reporting Person on February 25, 2022 was erroneously reported as 449,644 in the Original Form 4. F2 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on December 17, 2022, with the remainder vesting in eight substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 06:30 UTC | EQRx, Inc. EQRX · Entity 108311 | Exercise / conversionClass B Common Stock · Derivative | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-049125 · doc4.xml · derivative · entry 4 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion"). F1 · kind: Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion"). F1 · price: Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion"). F1 · derivative.exercise_date: Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion"). F1 · derivative.expiration_date: Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion"). Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 06:30 UTC | EQRx, Inc. EQRX · Entity 108311 | OtherCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-049125 · doc4.xml · nonDerivative · entry 3 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F2 · kind: Immediately following the Conversion but prior to Closing, the Class A Common Stock was reclassified as Common Stock. F2 · price: Immediately following the Conversion but prior to Closing, the Class A Common Stock was reclassified as Common Stock. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 06:30 UTC | EQRx, Inc. EQRX · Entity 108311 | OtherClass A Common Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-049125 · doc4.xml · nonDerivative · entry 2 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Immediately following the Conversion but prior to Closing, the Class A Common Stock was reclassified as Common Stock. F2 · price: Immediately following the Conversion but prior to Closing, the Class A Common Stock was reclassified as Common Stock. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 06:30 UTC | EQRx, Inc. EQRX · Entity 108311 | Exercise / conversionClass A Common Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-049125 · doc4.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion"). F1 · price: Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion"). Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 02:44 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0000899243-19-001830 · doc4.xml · derivative · entry 2 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 5,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vested on August 2, 2018 and 1/36th of the shares subject to the option vested or vest monthly thereafter. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 02:44 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,000 | $12.88 | $64,400.00 |
DisclosureSEC source: 0000899243-19-001830 · doc4.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 02:12 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 437 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000353 · doc4.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,837 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. F2 · balance_after: Includes 2,500 restricted stock units granted on July 1, 2018, the vesting of which was accelerated in full by the Issuer on December 17, 2018. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 01:14 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-025911 · doc4.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 21:35 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0000899243-18-019278 · doc4.xml · derivative · entry 2 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-07-01 F2 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on August 2, 2018 and 1/36th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 21:35 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019278 · doc4.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: The reported securities are represented by restricted stock units 1/3rd of which shall vest on July 1, 2019 and 1/3rd of which shall vest on each anniversary thereafter. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 18:18 UTC | ATHENAHEALTH INC ATHN · Entity 160326 | GrantCommon Stock | 1,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001131096-18-000143 · wf-form4_152849627907207.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,976 F1 · shares: Represents an award of restricted stock units ("RSUs") under the Issuer's 2007 Stock Option and Incentive Plan, as amended and restated (the "2007 Plan"), granted pursuant to the Issuer's 2018 Director Compensation Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs fully vest on June 6, 2019. F2 · balance_after: Includes 1,931 units of common stock that were granted pursuant to RSU awards under the 2007 Plan. The RSUs are subject to time-based vesting and will be settled only in stock. Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 21:38 UTC | ATHENAHEALTH INC ATHN · Entity 160326 | SaleCommon Stock | 500 | $134.18 | $67,090.00 |
DisclosureSEC source: 0001131096-17-000191 · wf-form4_151451506433306.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,045 F1 · shares: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on October 25, 2017, in accordance with Rule 10b5-1. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:49 UTC | ATHENAHEALTH INC ATHN · Entity 160326 | GrantCommon Stock | 1,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001131096-17-000034 · wf-form4_148857777082127.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,545 F1 · shares: Represents an award of restricted stock units ("RSUs") under the Issuer's 2007 Stock Option and Incentive Plan, as amended and restated, granted pursuant to the Issuer's 2017 Director Compensation Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs fully vest on March 1, 2018. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 16:18 UTC | ATHENAHEALTH INC ATHN · Entity 160326 | SaleCommon Stock | 1,000 | $117.15 | $117,150.00 |
DisclosureSEC source: 0001131096-16-000419 · wf-form4_148218227105716.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,649 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on September 9, 2016, in accordance with Rule 10b5-1. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 16:53 UTC | ATHENAHEALTH INC ATHN · Entity 160326 | SaleCommon Stock | 1,000 | $122.29 | $122,290.00 |
DisclosureSEC source: 0001131096-16-000378 · wf-form4_147319521795962.xml · nonDerivative · entry 1 Abernethy Amy · CIK 0001590728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,649 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on September 1, 2015, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.83 to $122.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote (2). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.